Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks

Information

  • Patent Grant
  • 8801647
  • Patent Number
    8,801,647
  • Date Filed
    Thursday, February 21, 2008
    16 years ago
  • Date Issued
    Tuesday, August 12, 2014
    10 years ago
Abstract
Method for treating a Roux-en-Y patient having fistulas and leaks as a result of bariatric surgery. A gastrointestinal implant device is anchored in the esophagus and extends through a stomach pouch into an intestine anastomosed to the stomach pouch to prevent fistulas and other damaged tissue from making contact with food and fluids entering the esophagus. The gastrointestinal implant device includes an unsupported flexible sleeve and an anchor coupled to a proximal portion of the sleeve. The flexible sleeve is open at both ends, and adapted to extend below a jejunum. The anchor is adapted to be retained within the esophagus, preferably just above the gastroesophageal (GE) Junction. The anchor can include a stent such as a wave anchor and is collapsible for catheter-based delivery and removal.
Description
BACKGROUND OF THE INVENTION

A fistula is an abnormal connection between organs. The rate of occurrence of leaks and fistulas following bariatric surgery ranges from 0.5% to 5%. These occur at staple lines in the gastric pouch or gastrojejunostomy in gastric bypass patients. Despite their relatively low incidence, leaks through fistulas can be life threatening and costly due to increased hospital stays and the need for antibiotics and parenteral nutrition. Regardless of its origin, pouch or gastrojejunostomy, fistulas can reach the skin (gastro- or enterocutaneous), the peritoneal cavity (abscess or peritonitis), adjacent stomach or bowel (gastro-gastric or gastro-enteric), and even the thorax and mediastinum.


The conventional treatment for relatively benign leaks is Nothing Per Oral (NPO) with parenteral nutritional support until the leak or fistula heals. If there is concurrent infection and sepsis, re-operation to suture, drain and gain enteral nutrition access may also be needed.


Experimental endoscopic approaches are being tried to close these leaks. These methods to close the fistula include fibrin glue, endoclips and packing the fistula with various biomaterials. These approaches result in successful healing in up to 70% of the cases, but they require at least three procedures per patient. Less severe gastro-enterostomy leaks and fistulas generally heal without intervention or with one endoscopic treatment. Gastric pouch fistulas are more difficult to close as surgical attempts generally fail.



FIG. 1 is a sectional view of a portion of the digestive tract in a body. Food to be digested enters the stomach 102 through the cardiac orifice 110 from the esophagus 120. The esophagus 120 is a tube that connects the pharynx (not shown) with the stomach 102. In an adult, the esophagus 120 may be about 10 inches long (250 mm). When a person swallows, the muscular walls of the esophagus contract to push food down into the stomach 120. Glands in the lining of the esophagus produce mucus, which keeps the passageway moist and facilitates swallowing. The Gastroesophageal (GE) Junction 122 has two sides, the esophageal side and the gastric side. The Lower Esophageal Sphincter (LES)) encircles the esophagus at the GE Junction 122 and is normally contracted to close the esophagus 120. When the GE Junction 122 closes, the contents of the stomach 102 cannot flow back into the esophagus 120.


Chyme, a semi-fluid, homogeneous creamy or gruel-like material produced by gastric digestion in the stomach exits the stomach through the pyloric orifice (pylorus) 108 and enters the small intestine 112. The pylorus 108 is a distal aperture of the stomach 102 surrounded by a strong band of circular muscle. The small intestine, about nine feet in length, is a convoluted tube, extending from the pylorus to the ileo-caecal valve where it terminates in the large intestine. The small intestine 128 has three sections, the duodenum 104, the jejunum 106 and the ileum (not shown). The first eight- to ten-inch section of the small intestine 128, the duodenum, is the shortest, widest and most fixed part of the small intestine.


The duodenum 104 has four sections: superior, descending, transverse and ascending which typically form a U-shape. The superior section is about two inches long and ends at the neck of the gall bladder. The descending section is about three to four inches long and includes a nipple shaped structure (papilla of vater) 114 through which pancreatic juice from the pancreas and bile produced by the liver and stored by the gall bladder enter the duodenum from the pancreatic duct. The pancreatic juice contains enzymes essential to protein digestion, and bile dissolves the products of fat digestion. The ascending section is about two inches long (50.8 mm) and forms the duodenal-jejunal flexure 116 where it joins the jejunum 106, the next section of the small intestine. The duodenal-jejunal flexure 116 is fixed to the ligament of Treitz 118 (musculus supensionus duodeni). The juices secreted in the duodenum break the partially digested food down into particles small enough to be absorbed by the body. The digestive system is described in Gray's Anatomy (“Anatomy of the Human Body”, by Henry Gray) and “Human Physiology”, Vander, 3rd ed., McGraw Hill, 1980, the contents of which are incorporated herein by reference in their entireties.


Gastric bypass surgery makes the stomach smaller and allows food to bypass part of the small intestine. A person will feel full more quickly than when the stomach was its original size, which reduces the amount of food one can eat and thus the calories consumed. Bypassing part of the intestine also results in fewer calories being absorbed. This leads to weight loss. The most common gastric bypass surgery is a Roux-en-Y gastric bypass. FIG. 2A is a sectional view of one surgical approach to a Roux-en-Y gastric bypass procedure. In this procedure, the surgeon first divides the stomach and creates a small stomach pouch 202 using staples 206, and then constructs a “bypass” for food. The small pouch 202 is about 40 to 60 cc. The bypass allows food to skip parts of the small intestine 128. By skipping a large part of the small intestine 128, the body cannot absorb as many calories or nutrients.


To make the bypass, the surgeon then makes a cut about one foot below the stomach 102 (Points A and B), which may be in the jejunum 106. Then a new 0.5 inch (15 mm) opening (stoma) is created in the small stomach pouch 202 (Point C). Referring to FIG. 2B, the surgeon then attaches the open end of the small intestine (Point B) to the new opening at Point C, creating a Roux limb 208. The Roux limb 208 carries food and fluids from the stomach pouch 202 into the lower portion of the small intestine 128.


The remaining end at Point A is stapled to close the opening. A new opening is created at Point D. The surgeon attaches Point A′ to the new opening at Point D, creating a “Y-shaped” or “Y-limb” intestinal junction 210. The Y-limb carries digestive juices from the bypassed stomach, pancreas, liver, and duodenum to the remaining intestines. The opening is made at Point D to allow digestive juices to flow into the lower portion of the small intestine 128.


Although the Roux-en-Y Procedure is an effective weight loss procedure, there are risks associated with such a procedure. For example, fistulas 205 and leaks can occur at the staple linings 206 and more typically at the stoma (Point B to C). Attempts have been made to treat these fistulas and leaks surgically and by covering them with stents that were typically designed to open strictures. For example, the Ultraflex™ Esophageal NG Stent System and Polyflex™ stents by Boston Scientific Corporation and the stents by Cook® Medical Incorporated, as well as the Choo stent (for example as in the Journal article by Steimann, R. U.; Zundler, J.; Kreichgauer, H. P.; Bode, J. C. (2000). A new stent device (Choo stent) for palliation of malignant gastric outlet obstruction. Endoscopy, 32 (5)) have been used to cover fistulas and/or leaks.


SUMMARY OF THE INVENTION

There are problems associated with such use of stents. The stents were designed for permanent long term use rather than temporary use. It is difficult to remove the stents, and they may have open areas that permit tissue in-growth that results in tissue damage with surgical removal.


The stents do not have good position stability when positioned to cover a fistula. The stents were designed to be mounted over or well above the GE Junction, so when the practitioner moves the stent down the esophagus to cover the fistulas and/or leaks, these stents lose stability and frequently migrate.


Further, due to the rigidity of the stents, the stents dilate the fistulas and/or leaks thereby causing irritation and ischemic pressure on the fistulas and/or leaks. The dilation of the anastomosis also counters the goal of having a restricted passageway from the stomach to the intestine for weight loss.


The present invention provides a method for treating a Roux-en-Y patient having fistulas and/or leaks as a result of bariatric surgery. A gastrointestinal implant device is anchored in the esophagus. The implant may include an anchor coupled to a proximal portion of a flexible, floppy sleeve, open at both ends and unsupported at a distal portion extending beyond the anchor. The flexible, floppy sleeve is extended through a stomach pouch into an intestine anastomosed to the stomach pouch. The sleeve prevents or shields fistulas and leaks from making contact with food and/or fluids.


The length of the sleeve can be varied, but at least extends through the stomach pouch into an intestine joined to the stomach pouch. In some embodiments, the sleeve extends into the jejunum.


The flexible, floppy sleeve imposes no outward pressure on the fistula, leak, or anastomosis. Advantageously, the material of the sleeve is slippery so as not to irritate the fistulas and/or leaks, thereby allowing the fistulas and/or leaks to heal. In preferred embodiments, the sleeve material has a coefficient of friction of less than about 0.2. The sleeve may be formed of a biocompatible, low-friction material such as a fluoropolymer. Preferably, the sleeve is formed of expanded polytetrafluoroethylene (ePTFE). Additionally, the sleeve may be coated or impregnated with a second material, such as Teflon® Fluorinated Ethylene Propylene (FEP), polyurethane, or silicone to reduce permeability. Still further, the distal end of the sleeve may be directionally textured.


The anchor may be collapsible for ease of insertion and/or removal. For example, the anchor may be inserted and/or removed endoluminally using a catheter-based procedure. The collapsible anchor is also well adapted for retention in the esophagus, being capable of collapsing and/or flexing in response to natural movements of the local anatomy. The anchor can be covered by a membrane, such as a proximal portion of the sleeve, and in some embodiments is sandwiched between a first inner layer of membrane and a second outer layer of membrane.


In another aspect, the anchor is a stent. Preferably the stent is a wave anchor. The wave anchor includes a compliant, radial spring shaped into an annular wave pattern about a central axis, providing an outward radial force, while allowing substantial flexure about its perimeter. Such flexure is advantageous as it allows for minimally-invasive delivery and ensures that the device will substantially conform to the surrounding anatomical structure when implanted. The annular wave element can be formed from one or more elongated resilient members and defines a lumen along its central axis formed between two open ends. When implanted, the central axis of the anchor is substantially aligned with the central axis of the esophagus, allowing food and fluids to pass through the device. Additionally, the compliant wave anchor minimizes trauma to the tissue by providing sufficient flexibility and compliance, while minimizing the likelihood of tissue erosion and providing a solid anchoring point to the tissue.


When implanted, the anchor enables a sleeve to be securely implanted within the esophagus, preferably providing a fluid seal at the proximal end. To enhance a fluid seal, the proximal end of the sleeve can be contoured along a leading edge of the wave anchor. Thus, food and fluids are allowed to flow substantially unimpeded into the sleeve without becoming entrapped at the anchor.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.



FIG. 1 is a sectional view of a portion of the digestive tract in a body;



FIGS. 2A-2B are sectional views of a Roux-en-Y gastric bypass procedure;



FIG. 3 is a sectional view of a body showing one embodiment of the gastrointestinal implant device implanted in the esophagus of a Roux-en-Y patient;



FIG. 4 is a perspective view of a gastrointestinal implant device according to the principles of the present invention;



FIG. 5 is a more-detailed perspective view of the anchoring device of FIG. 4;



FIG. 6 is a perspective view of an alternative embodiment of the gastrointestinal implant device of FIG. 4.



FIG. 7 illustrates an embodiment of a gastrointestinal implant device with a wave anchor and drawstrings;



FIG. 8 is a perspective view of a gastrointestinal implant device with another embodiment of an anchoring device;



FIG. 9 is a schematic view of an assembled delivery catheter system for delivery of the gastrointestinal implant device;



FIGS. 10A-10B are snapshot diagrams illustrating the placement of the gastrointestinal implant device;



FIG. 11 is a schematic diagram showing an exemplary embodiment of the invention repositioning device; and



FIG. 12 is a schematic diagram showing an exemplary embodiment of the invention capturing a proximal portion of an implantable device.





DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.


A fistula is an abnormal connection between organs. Fistulas and leaks can occur as a result of bariatric surgery, in particular after a Roux-en-Y gastric bypass procedure. A gastrointestinal implant device is anchored in the esophagus and extends through a stomach pouch into an intestine anastomosed to the stomach pouch to prevent fistulas and other damaged tissue from making contact with food and/or fluids entering the esophagus, thus enabling healing of the damaged tissue.



FIG. 3 is a sectional view of a body showing one embodiment of the gastrointestinal implant device 400 implanted in the esophagus, preferably just above the GE Junction 122. The device 400 includes an anchor and a sleeve. The anchor may have drawstrings to facilitate the removal of the implant device 400. The anchor has a relaxed diameter of 0.7-1.5 inches (20-40 mm). The sleeve attached to the anchor may be at least 6 inches (150 mm) long to pass from the esophagus, over the fistulas and/or leaks, and through the small pouch into an intestine anastomosed to the small pouch.


The gastrointestinal implant device has little or no tissue adhesion into the anchor or sleeve. Moreover, retrieval sutures (or drawstrings) make removal simple which is important for temporary usage until the fistulas and/or leaks heal. The sleeve extends over the leak and/or fistula area, preventing food and saliva from contacting the area without putting compression on the area. Further, the flexible floppy sleeve has no hoop strength, so that it can fall flat until food and/or fluids pass through. The lack of hoop strength allows the sleeve to collapse with no resistance to any applied inward force and itself imposes no outward dilating force. In this way, the sleeve allows the fistula and/or leaks to heal without ischemic pressure from an internal device.


The first proximal end 404 (FIG. 4) of the implant device 400 (FIG. 4) is anchored just above the GE Junction 122 of the esophagus 120. The stent 408 (FIG. 4) is collapsible and has a diameter that is larger than the diameter of the GE Junction 122. The diameter of the stent 408 (FIG. 4) has a relaxed diameter within the range of 0.7-1.5 inches (20-40 mm). As a result, the stent 408 (FIG. 4) has good positional stability because the radial outward force abuts the muscle of the esophagus 120. This in combination with the longitudinal support by the GE Junction 122 anchors the implant device 400 (FIG. 4) in place so that the implant device 400 can not be dragged into the small stomach pouch 202 or down into the Roux limb 208 and intestines with movement of the stomach pouch and the intestines. The small stomach pouch lacks the very strong peristaltic action of a normal stomach that would pull the anchor loose. The GE Junction 122 may continue to normally contract to prevent contents of the stomach 102 to flow back into the esophagus 120. The sleeve 402 (FIG. 4) extends into the Roux limb 208 and may extend beyond the proximal jejunum 106.


After the gastrointestinal implant device 400 (FIG. 4) has been placed in the body and anchored just above the GE Junction 122 of the esophagus 120, food and fluids entering the esophagus 120 (FIG. 1) passes through passageway 404 (FIG. 4) inside the sleeve 402 (FIG. 4). By directing the food and fluids through the sleeve 402 any fistulas and/or leaks on the way and in particular at the stoma (Point B to C of FIG. 2B) will be prevented from making contacts with food and fluids, thereby allowing the fistulas and/or leaks to heal. The slippery, flexible, floppy sleeve 402 (FIG. 4) is able to go through the stoma without causing ischemic pressure and/or irritation to the fistulas 205 and/or leaks.



FIG. 4 is a perspective view of a gastrointestinal implant device 400 according to the principles of the present invention. The gastrointestinal implant device 400 includes an elongated open-ended flexible sleeve 402 having a first proximal opening 404 and a distal opening 406. Within the sleeve 402 is a passageway that extends from the first proximal opening 404 to the second distal opening 406 for transporting the food (typically liquid food) and fluids entering the esophagus 120 (FIG. 1). The surface of the passageway (the interior surface of the implant device 400) is smooth to enable the food and fluids to easily pass through. The exterior surface of the implant device 400 is smooth to prevent tissue in-growth and to be non-irritating to the esophagus. In one embodiment, the length L of the flexible, floppy sleeve 402 is selected to extend through the small stomach pouch 202 (FIG. 2A) into an intestine anastomosed to the stomach pouch 202 (FIG. 2A) and covering any fistulas 205 (FIG. 2B) and/or leaks.


Within the implant device 400, at the proximal end including the first proximal opening 404, is a collapsible self-expanding anchor 408. The diameter of the anchor 408 is dependent on the diameter of the gastroesophageal (GE) Junction 122 (FIG. 1) and is in the range of about 0.7-1.5 inches (20-40 mm) based on human anatomy variations, typically about 25 mm. The anchor 408 may be a collapsible self-expanding stent.


The sleeve 402 material is thin and conformable so that it collapses in the intestine to a small volume to minimize esophagus irritability. It has a low coefficient of friction (<0.20) so that food and fluids slide easily through it and the esophagus slides easily around it. It is of low permeability to fluids so that the food and fluids do not touch the esophagus wall. It is biologically inert and non-irritating to the tissues. One such material is expanded polytetrafluoroethylene (ePTFE), a fluoropolymer, with a wall thickness of about 0.0005-0.001 inches (0.012-0.025 mm) and an internodal distance of 20 microns. This material is hydrophobic but is slightly porous. However, these very small pores may plug over time. The porosity may be reduced by coating the material on the inside, outside or in the pores with dilute solutions, such as Teflon®Fluorinated Ethylene Propylene (FEP), silicone, or polyurethane. Another material is polyethylene with a wall thickness of less than 0.001 inches (0.025 mm). Rubber-like materials typically have friction coefficients of 1-4, significantly stickier than these materials. However, in alternate embodiments other materials having similar characteristics can be used.


The overall length 412 of the sleeve 402, including the anchor is at least long enough to go through the small stomach pouch 202 (FIG. 2A). To that end, the overall length 412 may be at least 6.0 inches (150 mm). A longer sleeve 402, for example, greater than one foot (30 cm), may extend down through the Roux limb 208 (FIG. 2B) into the jejunum 106 (FIG. 1). The length 412 of the sleeve 402 may be selected to bypass a portion of the jejunum 106.


Markings can be added to the exterior surface of the sleeve 402 to detect the position and orientation of the sleeve on a fluoroscopic image and whether the sleeve is twisted. For example, a stripe can be painted down the length of the device 400 using tantalum impregnated ink, or tantalum bands can be bonded to the exterior surface of the device.


For more details regarding the sleeve, reference U.S. Pat. No. 7,267,694 filed Nov. 30, 2004, entitled “Bariatric sleeve,” which is hereby incorporated by reference in its entirety. The sleeve as cited in the above reference is anchored in the intestine and has different diameter and length than discussed in this application. Further, the cited reference includes barbs; however, in this application, preferably no barbs are required to anchor the implant in the esophagus.


The implant device 400 may include a wave anchor 410 coupled to a proximal portion 404 of the sleeve 402. Referring to FIG. 5, the wave anchor 410 includes a compliant, radial spring 502 shaped into an annular wave pattern about a central axis 504, providing an outward radial force, while allowing substantial flexure about its perimeter. Such flexure is advantageous as it allows for minimally-invasive delivery and ensures that the device will substantially conform to the surrounding anatomical structure when implanted. The annular wave element 502 can be formed from one or more elongated resilient members and defines a lumen along its central axis formed between two open ends. When implanted, as shown in FIG. 3, the central axis of the anchor 410 is substantially aligned with the central axis of the esophagus 120, allowing food and fluids to pass through the device 400. Additionally, the compliant wave anchor 410 minimizes trauma to the tissue by providing sufficient flexibility and compliance, while minimizing the likelihood of tissue erosion and providing a solid anchoring point to the tissue of the GE Junction 122. For more details regarding the compliant wave anchor 410, reference U.S. patent application Ser. No. 11/147/992 filed Jun. 8, 2005, entitled “Gastrointestinal Anchor Compliance” and U.S. patent application Ser. No. 10/858,851 filed Jun. 1, 2004, entitled “Intestinal Sleeve,” which are hereby incorporated by reference in their entireties. The sleeve as cited in the above references has different diameter and length than discussed in this application. Further, the cited references include barbs; however, in this application, preferably no barbs are required to anchor the implant in the esophagus.


The compliant wave anchor 410 can be manufactured from a resilient metal such as a heat-treated spring steel, stainless steel, or from an alloy such as NiTi alloy commonly referred to as Nitinol. Other alloys include nickel-cobalt-chromium-molybdenum alloys possessing a unique combination of ultrahigh tensile strength, such as MP35N. Additionally, the wave anchor 410 can be formed from a polymer and/or a composite having similar properties. The wave anchor 410 can be manufactured from a single strand, such as a wire, contoured into the desired shape. Alternatively, the wave anchor 410 can be manufactured from multi-strands of the same or different materials similarly contoured to the desired shape. In some embodiments, the wave anchor 410 can be cut into the wave shape from tubular stock of the desired material, such as Nitinol.


The anchor 410 can be removably attached within the body using any of the methods described herein for securing an anchor, including the possible use of barbs attached to, and/or formed on the anchor itself. Preferably, the anchor 410 is radially collapsible for endoscopic insertion. When implanted, the anchor enables a sleeve, or barrier to be securely implanted within the esophagus 120, preferably providing a fluid seal at the proximal end. To enhance a fluid seal, the proximal end of the sleeve can be contoured to the wave anchor 410 as shown in FIG. 6. For a device 400 using a sleeve 402 contoured to the wave anchor 410, the proximal end appears tulip-shaped.


Continuing with FIG. 6, the wave anchor 408 may be sandwiched between a first outer layer membrane 610 and a second inner layer membrane 615 at the proximal end of the sleeve 402. Preferably the sleeve 402 is an extension of the first outer layer of the membrane 605. The covered exterior surface of the stent 605 prevents tissue growth to allow removal of the implant device 400. The covered interior surface of the stent 605 provides a smooth passageway for food and fluids to bypass part of the jejunum 106. The diameter of the sleeve 402 is selected such that the first outer layer of the membrane 610 fits over the stent 605.



FIG. 7 illustrates an embodiment of a gastrointestinal device with a wave anchor and drawstrings. The anchor 408 can be configured with a drawstring 705. The drawstring 705 can facilitate repositioning and/or removal of the implant device 400. The drawstring 705 is shown woven through pairs of eyelets 780 distal to the wave peak 750 in the webbing material 770. The implantable device 400 can also include a second drawstring 790 distal to drawstring 705. This drawstring can also be woven through pairs of eyelets 795 distal to eyelets 780 for drawstring 705. The second drawstring 790 is an alternative drawstring in the situation that the first drawstring 705 breaks during repositioning or removal. The drawstring, when pulled, contracts about the perimeter of the anchor 408, thereby reducing the diameter of the anchor 408. Thus, the drawstring can be used to facilitate removal of an implanted anchor 408 by pulling it away from the surrounding anatomy.


Although the preferred embodiments do not need or use barbs for anchoring the implant device 400 just above the GE Junction 122, the anchor 408 may include a plurality of opposing barbs (not shown). The barbs may protrude from the exterior surface of the anchor 408 through the first outer layer of the sleeve 402.


A flexible, anti-rotation, anti-buckling mechanism (not shown) may be attached to the sleeve 402 and extends from below the distal end of the anchor along the length of the sleeve to the distal end of the sleeve 406. For more details regarding the anti-buckling mechanism, reference U.S. patent application Ser. No. 10/858,851 filed Jun. 1, 2004, entitled “Intestinal Sleeve” and U.S. patent application Ser. No. 11/494,284 filed Jul. 27, 2006, entitled “Anti-buckling sleeve,” which are hereby incorporated by reference in their entireties.



FIG. 8 is a perspective view of a gastrointestinal implant device 800 with another embodiment of a collapsible self-expanding stent anchoring device. The anchor 802 includes a plurality of flat struts 804 forming an open space pattern to ease collapsing while ensuring self-expansion. The open space pattern allows for collapsing into a catheter for endoscopic delivery and removal. The struts 804 may be manufactured from heat-treated spring steel such as Nitinol or MP35N.


In the embodiment shown, the anchor 802 has a length L of about 0.9-1.5 inches (25-40 mm) and has a relaxed diameter D of 0.7-1.5 inches (20-40 mm). The struts 804 are flat, about 0.010 inches wide (0.2 mm) and about 0.004-0.010 inches (0.1 to 0.2 mm) thick. The anchor can be formed from a tube of material by laser cutting followed by expansion and heat setting, or other methods well known to those skilled in the art.


In an alternate embodiment, the struts 804 can be formed separately and the strut intersections can be welded or attached by other means well known to those skilled in the art.



FIG. 9 is a schematic view of an assembled delivery catheter system for delivery of the gastrointestinal implant device of 400, 800. Typically, the sleeve and anchor are delivered transorally through the mouth. As shown in FIG. 9, delivery catheter system 900 includes an atraumatic tip comprising atraumatic ball 902, a container assembly that includes capsule or container 904, outer catheter 906, and inner catheter 910. Inner and outer catheters 910, 906 and container 904 are made from materials commonly used to form catheters. For example, inner catheter 910 can be made of a polyether block amide (e.g., Pebax® 7233, available from Arkema Group, Paris, France). In some embodiments, outer catheter 906 is made of high density polyethylene and/or container 904 is made of hard plastic (e.g., acetal or polycarbonate). Preferably, catheters 910, 906 are made from materials having frictional properties that facilitate the movement of catheter 910 relative to catheter 906 and facilitate the movement of inner catheter 910 and container 904 in the gastrointestinal tract. System 900 includes ball locking wire knob 930 and stiffening wire knob 932. Ball locking wire knob 930 extends from ball locking wire port 914 to distal end 902 via ball locking wire lumen (not shown) defined by inner catheter 910. Stiffening wire knob 932 extends from stiffening wire port 916 to distal end 902 via stiffening wire lumen (not shown) defined by inner catheter 910.


System 900 includes anchor locking wire 934, a means for displacing an anchor from the container assembly that includes anchor plunger 938, and guidewire 956. Anchor locking wire 934 extends from anchor locking wire port 936 to container 904 via anchor locking wire lumen (not shown) defined by outer catheter 906. Anchor plunger 938 extends from anchor plunger port 940 to container 904 via anchor plunger lumen (not shown) defined by outer catheter 906.


For more details regarding the catheter system for the delivery of the gastrointestinal implant devices 400, 800, reference U.S. patent application Ser. No. 11/057,861 filed Feb. 14, 2005, entitled “Methods and devices for placing a gastrointestinal sleeve,” which is hereby incorporated by reference in its entirety.



FIGS. 10A-10B are snapshot diagrams illustrating example embodiments of methods of the invention. A gastro-scope (not shown) is directed through the mouth of a patient, and into the esophagus 120. A length of guidewire (not shown) is directed through the working channel of gastro-scope (not shown), out of the distal end, and into the proximal portion of the esophagus. Once a sufficient length of guidewire is in the desire location, gastro-scope can be removed while guidewire is held in position.


Once the guidewire is in the desired location and the gastro-scope has been removed, a delivery catheter is directed into the esophagus. The leading or distal end of outer catheter 906 is attached, assembled to, or comprises a capsule or container assembly that includes capsule or container 904. Container 904 defined a guidewire lumen along its side. The proximal end of guidewire is directed through the guidewire lumen, and catheter 906 is advanced or directed along guidewire to a point distal from the GE Junction 122 and into a desired position in the esophagus. Optionally, the location of capsule 904 is confirmed using fluoroscopy.


Once container 904 is at the desired location in the esophagus, guidewire can be removed from the esophagus, as illustrated in FIG. 10A with the guidewire removed. Optionally, prior to insertion, a lubricating jelly is applied to the surface of those portions of catheter 906 that are inserted into the esophagus.


The container holds or houses parts or all of a gastrointestinal implant device (e.g., a gastrointestinal sleeve). The gastrointestinal implant device includes a distal portion and a proximal portion. The distal portion includes a gastrointestinal sleeve and the proximal portion of the device includes an anchor for securing the device within the esophagus. In some embodiments, the container holds or houses the proximal portion of the gastrointestinal device. In other embodiments, the container holds or houses both the distal and proximal portions. In still further embodiments, the container holds or houses the entire gastrointestinal device. Some or all of the sleeve portion can be folded and stored in the container with the anchor.


After container 904 is at the desired location in the esophagus, a distal portion 1106 of the sleeve is removed from the container and directed into a location in the esophagus that is distal from the container. Outer catheter 906 defines an inner catheter lumen, and an inner catheter, to which ball 902 is releasably attached, is directed through the inner catheter lumen and into locations of the esophagus that are distal from container 904 and esophagus.


For more details regarding the delivery of the gastrointestinal implant devices 400, 800, reference U.S. patent application Ser. No. 11/057,861 filed Feb. 14, 2005, entitled “Methods and devices for placing a gastrointestinal sleeve,” U.S. patent application Ser. No. 11/302,977 filed Dec. 13, 2005, entitled “Atraumatic delivery devices,” U.S. patent application Ser. No. 11/001,794 filed Nov. 30, 2004, entitled “Bariatric sleeve delivery devices,” and U.S. Pat. No. 7,122,058 filed Dec. 2, 2003, entitled “Anti-obesity devices,” which are hereby incorporated by reference in their entireties.



FIG. 11 is a schematic diagram showing an exemplary embodiment of a repositioning and retrieval device for the gastrointestinal implant device 400, 800. The repositioning and retrieval device can be used to remove the sleeve and anchor transorally through the mouth once the leaks and/or fistulas have healed. The repositioning and retrieval device 1100 may include a handle 1110 adapted to attach to an actuator 1120 for maneuvering the actuator 1120. The repositioning device 1100 further may include an elongated member 1150. The actuator 1120 is adapted to attach to a proximal end of the elongated member 1150. The repositioning device 1100 further may include an elongated tube 1140. The elongated tube 1140 defines a lumen within which the elongated member 1150 is slidably disposed. The elongated tube 1140 is adapted for insertion into a natural bodily lumen.


A grasper 1160 is coupled at a distal end of the elongated member 1150 and is adapted to grasp a feature of an implantable device 400, 800. For example, a drawstring 705 can be provided such that manipulation of the drawstring 705 can reduce at least one dimension (e.g., the diameter) of the implantable device 400, 800.


The proximal end of the elongated member 1150 is coupled to the actuator 1120. Similarly, a proximal end of the elongated tube 1140 is coupled to the handle 1110. The handle 1110 and the actuator 1120 may be operated manually from a site external to a body. For example, the handle 1110 and the actuator 1120 can be used to maneuver the elongated member 1150.


The repositioning device 1100 may further include an outer tube 1130. The outer tube 1130 also defined a lumen within which the elongated tube 1140 may be slidably disposed.


In some embodiments, the retrieval hood 1190 is coupled to the outer tube 1140 using an interference fit. In other embodiments, the retrieval hood 1190 may be coupled to the outer tube 1140 using alternative mechanical, chemical, or bonding techniques.



FIG. 12 is a snapshot schematic diagram showing an exemplary embodiment of the invention capturing a proximal portion of an implantable device. The grasper is adapted to grasp a portion of the implantable device, such as a drawstring of a gastrointestinal liner or stent. When the drawstring is grasped and moved linearly, at least a portion of the implantable device radially collapses. The grasped device can then be repositioned within the natural bodily lumen. In some instances, the grasped device can be removed from the natural bodily lumen together with the inner tube. The grasper may be a hook or other structure that is capable of grasping a portion of the implantable device, such as a drawstring. A shown in FIG. 12, the grasper 1160 extending distally beyond the inner tube 1240, engages a portion of the drawstring 705 of the implantable device 400. The actuator 1120 is then used to proximally draw the grasper 1160 and the engaged portion of the drawstring 705 (as indicated by arrow I). For more details regarding the removal and repositioning devices, reference U.S. patent application Ser. No. 11/318,083 filed Dec. 22, 2005, entitled “Removal and repositioning devices,” which is hereby incorporated by reference in its entirety.


While this invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Claims
  • 1. A method of treatment of a fistula or leak of a Roux-en-Y patient comprising the steps of: selecting a Roux-en-Y patient having a fistula or leak as a result of bariatric surgery;providing an implant comprising a collapsible, self-expanding anchor coupled to a proximal portion of a flexible, floppy sleeve, open at both ends, a distal portion of the flexible, floppy sleeve extending beyond the anchor and being unsupported;positioning the anchor within the esophagus of the patient, who has had a Roux-en-Y gastric bypass procedure, and above the gastroesophageal (GE) Junction of the patient; andextending the flexible, floppy sleeve through a stomach pouch of the patient past the fistula or leak into an intestine anastomosed to the stomach pouch.
  • 2. The method of claim 1 wherein the anchor is a stent.
  • 3. The method of claim 1, wherein the anchor has a relaxed diameter of 20 to 40 millimeters.
  • 4. The method of claim 1, wherein the anchor has a length of 25 to 40 millimeters.
  • 5. The method of claim 1, wherein the anchor is a wave anchor.
  • 6. The method of claim 1, wherein the anchor is covered with a membrane.
  • 7. The method of claim 1, wherein the anchor is sandwiched between a first inner layer of membrane and a second outer layer of membrane.
  • 8. The method of claim 1, wherein the implant has a length of at least 150 mm.
  • 9. The method of claim 1, wherein the sleeve and anchor are delivered using an esophageal catheter.
  • 10. The method of claim 1, wherein the sleeve and anchor are removed transorally through the mouth.
  • 11. The method of claim 1, wherein the anchor includes a drawstring to facilitate the removal of the anchor.
  • 12. The method of claim 1, wherein the sleeve shields fistulas and leaks from making contact with food and fluids entering the esophagus.
RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/902,705, filed on Feb. 22, 2007, and U.S. Provisional Application No. 61/005,437, filed on Dec. 5, 2007. The entire teachings of the above applications are incorporated herein by reference.

US Referenced Citations (353)
Number Name Date Kind
1899781 Twiss Feb 1933 A
2464933 Kaslow Mar 1949 A
3780740 Rhea Dec 1973 A
4133315 Berman et al. Jan 1979 A
4134405 Smit Jan 1979 A
4246893 Berson Jan 1981 A
4265694 Boretos et al. May 1981 A
4270542 Plumley Jun 1981 A
4271827 Angelchik Jun 1981 A
4279251 Rüsch Jul 1981 A
4315509 Smit Feb 1982 A
4341218 Hoi Jul 1982 A
4403604 Wilkinson et al. Sep 1983 A
4416267 Garren et al. Nov 1983 A
4501264 Rockey Feb 1985 A
4580568 Gianturco Apr 1986 A
4607618 Angelchik Aug 1986 A
4617932 Kornberg Oct 1986 A
4641653 Rockey Feb 1987 A
4648383 Angelchik Mar 1987 A
4763653 Rockey Aug 1988 A
4768507 Fischell et al. Sep 1988 A
4823808 Clegg et al. Apr 1989 A
4846836 Reich Jul 1989 A
4878905 Blass Nov 1989 A
4905693 Ravo Mar 1990 A
4913141 Hillstead Apr 1990 A
5035706 Gianturco et al. Jul 1991 A
5037387 Quinn et al. Aug 1991 A
5041126 Gianturco Aug 1991 A
5057091 Andersen Oct 1991 A
5059166 Fischell et al. Oct 1991 A
5104399 Lazarus Apr 1992 A
5123917 Lee Jun 1992 A
5135516 Sahatjian et al. Aug 1992 A
5152756 Quinn et al. Oct 1992 A
5152782 Kowligi et al. Oct 1992 A
5176617 Fischell et al. Jan 1993 A
5190561 Graber Mar 1993 A
5236423 Mix et al. Aug 1993 A
5246456 Wilkinson Sep 1993 A
5254133 Seid Oct 1993 A
5279553 Winkler et al. Jan 1994 A
5282824 Gianturco Feb 1994 A
5290294 Cox et al. Mar 1994 A
5306300 Berry Apr 1994 A
5314444 Gianturco May 1994 A
5314472 Fontaine May 1994 A
5314473 Godin May 1994 A
5318530 Nelson, Jr. Jun 1994 A
5322501 Mahmud-Durrani Jun 1994 A
5330500 Song Jul 1994 A
5364353 Corfitsen et al. Nov 1994 A
5387235 Chuter Feb 1995 A
5389090 Fischell et al. Feb 1995 A
5401241 Delany Mar 1995 A
5405378 Strecker Apr 1995 A
5417697 Wilk et al. May 1995 A
5443498 Fontaine Aug 1995 A
5456713 Chuter Oct 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5492530 Fischell et al. Feb 1996 A
5507767 Maeda et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5522880 Barone et al. Jun 1996 A
5562697 Christiansen Oct 1996 A
5569219 Hakki et al. Oct 1996 A
5571173 Parodi Nov 1996 A
5605530 Fischell et al. Feb 1997 A
5607442 Fischell et al. Mar 1997 A
5611787 Demeter et al. Mar 1997 A
5624430 Eton et al. Apr 1997 A
5630797 Diedrich et al. May 1997 A
5634928 Fischell et al. Jun 1997 A
5639274 Fischell et al. Jun 1997 A
5643312 Fischell et al. Jul 1997 A
5662713 Andersen et al. Sep 1997 A
5665064 Bodicky et al. Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5690642 Osborne et al. Nov 1997 A
5693084 Chuter Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5713948 Uflacker Feb 1998 A
5715832 Koblish et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5722984 Fischell et al. Mar 1998 A
5730698 Fischell et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735859 Fischell et al. Apr 1998 A
5735892 Myers et al. Apr 1998 A
5743874 Fischell et al. Apr 1998 A
5749825 Fischell et al. May 1998 A
5755777 Chuter May 1998 A
5759174 Fischell et al. Jun 1998 A
5776186 Uflacker Jul 1998 A
5792144 Fischell et al. Aug 1998 A
5792172 Fischell et al. Aug 1998 A
5800456 Maeda et al. Sep 1998 A
5800526 Anderson et al. Sep 1998 A
5820584 Crabb Oct 1998 A
5830229 Konya et al. Nov 1998 A
5840009 Fischell et al. Nov 1998 A
5843164 Frantzen et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5861036 Godin Jan 1999 A
5876445 Andersen et al. Mar 1999 A
5879282 Fischell et al. Mar 1999 A
5879370 Fischell et al. Mar 1999 A
5895391 Farnholtz Apr 1999 A
5910145 Fischell et al. Jun 1999 A
5913895 Burpee et al. Jun 1999 A
5919233 Knopf et al. Jul 1999 A
5925063 Khosravi Jul 1999 A
5962620 Reich et al. Oct 1999 A
5963620 Frankel et al. Oct 1999 A
5964771 Beyar et al. Oct 1999 A
5976153 Fischell et al. Nov 1999 A
6013019 Fischell et al. Jan 2000 A
6027508 Ren et al. Feb 2000 A
6027526 Limon et al. Feb 2000 A
6035856 LaFontaine et al. Mar 2000 A
6074673 Guillen Jun 2000 A
6086604 Fischell et al. Jul 2000 A
6099552 Adams Aug 2000 A
6102887 Altman Aug 2000 A
6120533 Fischell Sep 2000 A
6120534 Ruiz Sep 2000 A
6132471 Johlin, Jr. Oct 2000 A
6146323 Fischell Nov 2000 A
6152956 Pierce Nov 2000 A
6179868 Burpee et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6190403 Fischell et al. Feb 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6221043 Fischell et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6241738 Dereume Jun 2001 B1
6241757 An et al. Jun 2001 B1
6251064 Silverman et al. Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6270521 Fischell et al. Aug 2001 B1
6293960 Ken Sep 2001 B1
6302891 Nadal Oct 2001 B1
6302917 Dua et al. Oct 2001 B1
6315708 Salmon et al. Nov 2001 B1
6322538 Elbert et al. Nov 2001 B1
6331190 Shokoohi et al. Dec 2001 B1
6332877 Michels Dec 2001 B1
6355056 Pinheiro Mar 2002 B1
6356782 Sirimanne et al. Mar 2002 B1
6375660 Fischell et al. Apr 2002 B1
6383214 Banas et al. May 2002 B1
6387114 Adams May 2002 B2
6401718 Johnson et al. Jun 2002 B1
6402779 Colone et al. Jun 2002 B1
6406792 Briquet et al. Jun 2002 B1
6428558 Jones et al. Aug 2002 B1
6450989 Dubrul et al. Sep 2002 B2
6458074 Matsui et al. Oct 2002 B1
6485409 Voloshin et al. Nov 2002 B1
6485515 Strecker Nov 2002 B2
6508833 Pavcnik et al. Jan 2003 B2
6520985 Burpee et al. Feb 2003 B1
6524335 Hartley et al. Feb 2003 B1
6524336 Papazolgou et al. Feb 2003 B1
6530951 Bates et al. Mar 2003 B1
6537247 Shannon Mar 2003 B2
6540775 Fischell et al. Apr 2003 B1
6540789 Silverman et al. Apr 2003 B1
6544291 Taylor Apr 2003 B2
6547817 Fischell et al. Apr 2003 B1
6558400 Deem et al. May 2003 B2
6558429 Taylor May 2003 B2
6565597 Fearnot et al. May 2003 B1
6589213 Reydel Jul 2003 B2
6589275 Ivancev et al. Jul 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635069 Teoh et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6645239 Park et al. Nov 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6656194 Gannoe et al. Dec 2003 B1
6669722 Chen et al. Dec 2003 B2
6675809 Stack et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6695875 Stelter et al. Feb 2004 B2
6699263 Cope Mar 2004 B2
6699278 Fischell et al. Mar 2004 B2
6706061 Fischell et al. Mar 2004 B1
6716240 Fischell et al. Apr 2004 B2
6736840 Fischell et al. May 2004 B2
6740121 Geitz May 2004 B2
6755869 Geitz Jun 2004 B2
6764518 Godin Jul 2004 B2
6773440 Gannoe et al. Aug 2004 B2
6776791 Stallings et al. Aug 2004 B1
6802868 Silverman et al. Oct 2004 B2
6821291 Bolea et al. Nov 2004 B2
6845776 Stack et al. Jan 2005 B2
6860901 Baker et al. Mar 2005 B1
6936065 Khan et al. Aug 2005 B2
6960233 Berg et al. Nov 2005 B1
7011673 Fischell et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7033384 Gannoe et al. Apr 2006 B2
7037327 Salmon et al. May 2006 B2
7037344 Kagan et al. May 2006 B2
7081132 Cook et al. Jul 2006 B2
7087088 Berg et al. Aug 2006 B2
7121283 Stack et al. Oct 2006 B2
7122058 Levine et al. Oct 2006 B2
7146984 Stack et al. Dec 2006 B2
7152607 Stack et al. Dec 2006 B2
7160312 Saadat Jan 2007 B2
7211114 Bessler et al. May 2007 B2
7220237 Gannoe et al. May 2007 B2
7220284 Kagan et al. May 2007 B2
7267694 Levine et al. Sep 2007 B2
7314489 McKenna et al. Jan 2008 B2
7329285 Levine et al. Feb 2008 B2
7338520 Bailey et al. Mar 2008 B2
7347875 Levine et al. Mar 2008 B2
7354454 Stack et al. Apr 2008 B2
7476256 Meade et al. Jan 2009 B2
20010020190 Taylor Sep 2001 A1
20020022853 Swanson et al. Feb 2002 A1
20020032487 Dua et al. Mar 2002 A1
20020065545 Leonhardt et al. May 2002 A1
20020091439 Baker et al. Jul 2002 A1
20020120277 Hauschild et al. Aug 2002 A1
20020143387 Soetikno et al. Oct 2002 A1
20020147489 Hong et al. Oct 2002 A1
20020151953 Chobotov et al. Oct 2002 A1
20020177890 Lenker Nov 2002 A1
20020183768 Deem et al. Dec 2002 A1
20020183786 Girton Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193828 Griffin et al. Dec 2002 A1
20030032941 Boyle et al. Feb 2003 A1
20030040804 Stack et al. Feb 2003 A1
20030040808 Stack et al. Feb 2003 A1
20030050684 Abrams et al. Mar 2003 A1
20030109892 Deem et al. Jun 2003 A1
20030109931 Geitz Jun 2003 A1
20030109935 Geitz Jun 2003 A1
20030120265 Deem et al. Jun 2003 A1
20030149467 Linder et al. Aug 2003 A1
20030153927 DiPoto et al. Aug 2003 A1
20030191476 Smit Oct 2003 A1
20030199989 Stack et al. Oct 2003 A1
20030199990 Stack et al. Oct 2003 A1
20030199991 Stack et al. Oct 2003 A1
20030208260 Lau et al. Nov 2003 A1
20030216749 Ishikawa et al. Nov 2003 A1
20030233140 Hartley et al. Dec 2003 A1
20040019388 Starkebaum Jan 2004 A1
20040024386 Deem et al. Feb 2004 A1
20040037865 Miller Feb 2004 A1
20040039452 Bessler Feb 2004 A1
20040044357 Gannoe et al. Mar 2004 A1
20040082963 Gannoe et al. Apr 2004 A1
20040092892 Kagan et al. May 2004 A1
20040092974 Gannoe et al. May 2004 A1
20040093065 Yachia et al. May 2004 A1
20040098079 Hartley et al. May 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117031 Stack et al. Jun 2004 A1
20040122452 Deem et al. Jun 2004 A1
20040122453 Deem et al. Jun 2004 A1
20040122470 Deem et al. Jun 2004 A1
20040133147 Woo Jul 2004 A1
20040136971 Scharp et al. Jul 2004 A1
20040138525 Saadat et al. Jul 2004 A1
20040138529 Wiltshire et al. Jul 2004 A1
20040138760 Schurr Jul 2004 A1
20040138761 Stack et al. Jul 2004 A1
20040143342 Stack et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040153167 Stack et al. Aug 2004 A1
20040158229 Quinn Aug 2004 A1
20040158331 Stack et al. Aug 2004 A1
20040172063 Li et al. Sep 2004 A1
20040172088 Knudson et al. Sep 2004 A1
20040172141 Stack et al. Sep 2004 A1
20040172142 Stack et al. Sep 2004 A1
20040172143 Geitz Sep 2004 A1
20040181242 Stack et al. Sep 2004 A1
20040193093 Desmond, III Sep 2004 A1
20040210243 Gannoe et al. Oct 2004 A1
20040220682 Levine et al. Nov 2004 A1
20040236401 Shin et al. Nov 2004 A1
20040249362 Levine et al. Dec 2004 A1
20050004681 Stack et al. Jan 2005 A1
20050043601 Kilcoyne et al. Feb 2005 A1
20050043817 McKenna et al. Feb 2005 A1
20050049718 Dann et al. Mar 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050075622 Levine et al. Apr 2005 A1
20050080395 Levine et al. Apr 2005 A1
20050080431 Levine et al. Apr 2005 A1
20050080491 Levine et al. Apr 2005 A1
20050085787 Laufer Apr 2005 A1
20050085923 Levine et al. Apr 2005 A1
20050090873 Imran Apr 2005 A1
20050096673 Stack et al. May 2005 A1
20050096750 Kagan et al. May 2005 A1
20050125020 Meade et al. Jun 2005 A1
20050125075 Meade et al. Jun 2005 A1
20050149114 Cartledge et al. Jul 2005 A1
20050171556 Murphy Aug 2005 A1
20050192614 Binmoeller Sep 2005 A1
20050216040 Gertner et al. Sep 2005 A1
20050216042 Gertner Sep 2005 A1
20050221072 Dubrow et al. Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050240279 Kagan et al. Oct 2005 A1
20050256587 Egan Nov 2005 A1
20050267499 Stack et al. Dec 2005 A1
20050267533 Gertner Dec 2005 A1
20060009858 Levine et al. Jan 2006 A1
20060064120 Levine et al. Mar 2006 A1
20060106332 Knudson et al. May 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060157067 Saadat et al. Jul 2006 A1
20060161139 Levine et al. Jul 2006 A1
20060161172 Levine et al. Jul 2006 A1
20060161187 Levine et al. Jul 2006 A1
20060161265 Levine et al. Jul 2006 A1
20060212042 Lamport et al. Sep 2006 A1
20060265082 Meade et al. Nov 2006 A1
20060287734 Stack et al. Dec 2006 A1
20060293742 Dann et al. Dec 2006 A1
20070005147 Levine et al. Jan 2007 A1
20070010864 Dann et al. Jan 2007 A1
20070027548 Levine et al. Feb 2007 A1
20070032879 Levine et al. Feb 2007 A1
20070049801 Lamport et al. Mar 2007 A1
20070083271 Levine et al. Apr 2007 A1
20070088389 Dunkin et al. Apr 2007 A1
20070293716 Baker et al. Dec 2007 A1
20080071383 Levine Mar 2008 A1
20080097466 Levine et al. Apr 2008 A1
20080103604 Levine et al. May 2008 A1
20080161787 Roslin Jul 2008 A1
20080223476 Stinson Sep 2008 A1
20080234834 Meade et al. Sep 2008 A1
20080269715 Faller et al. Oct 2008 A1
20090012544 Thompson et al. Jan 2009 A1
Foreign Referenced Citations (65)
Number Date Country
33 26 061 Feb 1984 DE
0 480 667 Apr 1992 EP
0278937 Oct 1993 EP
0 506 918 Jan 1996 EP
0754017 Jan 1997 EP
0843538 May 1998 EP
0 857 471 Aug 1998 EP
0935977 Aug 1999 EP
0935977 Aug 1999 EP
1 481 649 Dec 2004 EP
1 504 778 Feb 2005 EP
1 504 778 Mar 2005 EP
04212348 Aug 1992 JP
WO 9206734 Apr 1992 WO
WO 9703624 Feb 1997 WO
WO 0012027 Mar 2000 WO
WO 0028922 May 2000 WO
WO 0032137 Jun 2000 WO
WO 0042945 Jul 2000 WO
WO 0042949 Jul 2000 WO
WO 0112256 Feb 2001 WO
WO 0135861 May 2001 WO
WO 0145485 Jun 2001 WO
WO 02081019 Oct 2002 WO
WO 02096327 Dec 2002 WO
WO 03017882 Mar 2003 WO
WO 03086246 Oct 2003 WO
WO 03086247 Oct 2003 WO
WO 03086360 Oct 2003 WO
WO 03094785 Nov 2003 WO
WO 2004000169 Dec 2003 WO
WO 2004004542 Jan 2004 WO
WO 2004004542 Jan 2004 WO
WO 2004014237 Feb 2004 WO
WO 2004019765 Mar 2004 WO
WO 2004019765 Mar 2004 WO
WO 2004021894 Mar 2004 WO
WO 2004037064 May 2004 WO
WO 2004037064 May 2004 WO
WO 2004049982 Jun 2004 WO
WO 2004064680 Aug 2004 WO
WO 2004064682 Aug 2004 WO
WO 2004064685 Aug 2004 WO
WO 2004069331 Aug 2004 WO
WO 2004069332 Aug 2004 WO
WO 2004073782 Sep 2004 WO
WO 2004087014 Oct 2004 WO
WO 2004087233 Oct 2004 WO
WO 2004093639 Nov 2004 WO
WO 2004093639 Nov 2004 WO
WO 2005011533 Feb 2005 WO
WO 2005060869 Jul 2005 WO
WO 2005060882 Jul 2005 WO
WO 2005082296 Sep 2005 WO
WO 2005110280 Nov 2005 WO
WO 2005117716 Dec 2005 WO
WO 2005118049 Dec 2005 WO
WO 2005120363 Dec 2005 WO
WO 2006016894 Feb 2006 WO
WO 2006034062 Mar 2006 WO
WO 2006078781 Jul 2006 WO
WO 2006078927 Jul 2006 WO
WO 2006088578 Aug 2006 WO
WO 2006102012 Sep 2006 WO
WO 2006133311 Dec 2006 WO
Non-Patent Literature Citations (25)
Entry
Gray, Henry, “The Vascular System,” In Anatomy, Descriptive and Surgical, 15th Edition, (Bounty Books:NY), T.P. Pick and R. Howden, eds., pp. 1126-1128 (1977).
Parodi, J.C., M.D., “Endovascular Repair of Abdominal Aortic Aneurysms,” Advances in Vascular Surgery, vol. 1, pp. 85 105 (1993).
Rubino, F. and J. Marescaux, “Effect of Duodenal-Jejunal Exclusion in a Non-obese Animal Model of Type 2 Diabetes, A New Perspective for an Old Disease,” Annals of Surgery 239(1):Jan. 1-11, 2004.
Yates III, M. R., et al., “Palliation of Malignant Gastric and Small Intestinal Strictures With Self Expandable Metal Stents,” Endoscopy 30:266 272 (1998).
Bethge, N., et al., “Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses,” Gastrointestinal Endoscopy 43(6):596 602 (1996).
Binkert, C. A., et al., “Benign and Malignant Stenoses of the Stomach and Duodenum: Treatment with Self expanding Metallic Endoprostheses,” Radiology 199(2):335 338 (1996).
Cwikiel, W., et al., “Self expanding Stent in the Treatment of Benign Esophageal Strictures: Experimental Study in Pigs and Presentation of Clinical Cases,” Radiology 187(3):667 671 (1993).
Dolan, K. et al., “Treating Diabetes in the Morbidly Obese by Laproscopic Gastric Band,” Obesity Surgery, vol. 13, pp. 439 443 (2003).
Park, B.P. et al., Malignant Obstruction of Gastric Outlet and Duodenum: Palliation with Flexible Covered Metallic Stents, Radiology 219(3):679 683 (2001).
Dormann, A.J. et al., “Self expanding metallic stents for continous dilatation of benign stenosis in gastrointestinal tract first results of long term follow up in interim stent application in pyloric and colonic obstructions,” Z Gastroenteral 39:957 960 (2001).
Pories, W.J., “Why Does the Gastric Bypass Control Type 2 Diabetes Mellitus?” Obesity Surgery, 2:303 313 (1992).
Pories, W.J., et al., “Etiology of Type II Diabetes Mellitus: Role of the Foregut,” World J. Surg., 25:527 531 (2001).
Rubino, F., et al., “Potential of Surgery for Curing Type 2 Diabetes Mellitus,” Annals of Surgery 236(5): 554 559 (2002).
Sandha, G. S. and Marcon, N. E., “Expandable Metal Stents for Benign Esophageal Obstruction,” Gastrointestinal Endoscopy Clinics of North America 9:(3)437 446 (1999).
Feretis, C., et al., “Palliation of Malignant Gastric Outlet Obstruction with Self-Expanding Metal Stents,” Endoscopy 28:225-228 (1996).
CHOOSTENT™, Covered Esophageal Stent, Instructions, Retrieved from the Internet (http://mitech.co.kr/uploads/images/282/use guide esophachoo—english.pdf) on Jul. 26, 2005.
Hwang, J.C., et al., “Covered Retrievable Tracheobronchial Hinged Stent: An Experimental Study in Dogs,” J. Vasc. Interv. Radiol., 12(12):1429-1436 (Dec. 2001).
Irie, T., et al., “Relocatable Gianturco Expandable Metallic Stents1,” Radiology, 178:575-578 (1991).
Lee, B.H., et al., “New Self-Expandable Spiral Metallic Stent: Preliminary clinical Evaluation in Malignant Biliary Obstruction,” J. Vasc Interv Radiol., 6(4):635-640 (Jul. 8, 1995).
Lee, S.H., “The Role of Oesophageal Stenting in the Non-Surgical Management of Oesophageal Strictures,” British J. Radiology, 74:891-900 (Oct. 2001).
Shim, C.S., et al., “Fixation of a Modified Covered Esophageal Stent: Its Clinical Usefulness for Preventing Stent Migration,” Endoscopy, 33(10):843-848 (Oct. 2001).
Song, H.Y., et al., “Benign and Malignant Esophageal Strictures: Treatment with a Polyurethane-Covered Retrievable Expandable Metallic Stent1,” Radiology, 203(3):747-752 (Jun. 1997).
Song, H.Y., et al., “Covered Retrievable Expandable Nitinol Stents in Patients with Benign Esophageal Strictures: Initial Experience1,” Radiology, 217:551-557 (Nov. 2000).
Song, H.Y., et al., “Tracheobronchial Strictures: Treatment with a Polyurethane-Covered Retrievable Expandable Nitinol Stent—Initial Experience,” Radiology, 213:905-912 (Dec. 1999).
Yoon, C.J., et al., “Removal of Retrievable Esophageal and Gastrointestinal Stents: Experience in 113 Patients,” American J. of Roentgenology, 183:1437-1444 (Nov. 2004).
Related Publications (1)
Number Date Country
20080208357 A1 Aug 2008 US
Provisional Applications (2)
Number Date Country
60902705 Feb 2007 US
61005437 Dec 2007 US